What is the difference between the 23‑valent pneumococcal polysaccharide vaccine (PPSV23) and the 13‑valent pneumococcal conjugate vaccine (PCV13)?

Key Differences Between Pneumococcal Vaccines

The fundamental difference is that PCV13 (Prevnar 13) is a conjugate vaccine containing 13 serotypes that produces T-cell dependent immune responses with immunologic memory, while PPSV23 (Pneumovax 23) is a polysaccharide vaccine containing 23 serotypes that produces T-cell independent responses without generating lasting immunologic memory. 1, 2

Vaccine Composition and Serotype Coverage

PCV13 (13-valent Pneumococcal Conjugate Vaccine):

• Contains 13 pneumococcal serotypes (1,3,4,5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) conjugated to CRM197 carrier protein 3
• Each serotype polysaccharide is chemically linked to a protein carrier (diphtheria CRM197), which enables T-cell dependent immune responses 3

PPSV23 (23-valent Pneumococcal Polysaccharide Vaccine):

• Contains 23 pneumococcal serotypes, including 11 additional serotypes not found in PCV13 1
• These 11 unique serotypes account for 32-37% of invasive pneumococcal disease among adults ≥65 years 1
• Consists of unconjugated polysaccharides without protein carriers 4

Immunologic Mechanisms and Response Quality

Superior Immunogenicity of PCV13:

• PCV13 elicits significantly greater functional immune responses (measured by opsonophagocytic activity) than PPSV23 for the majority of the 12 shared serotypes 2, 5
• In vaccine-naive adults aged 60-64 years, PCV13 produced statistically significantly higher OPA titers than PPSV23 for 8 of 12 common serotypes, with comparable responses for the remaining 4 2
• The conjugate structure creates T-cell dependent immunity, generating immunologic memory and enabling booster responses upon revaccination 4

Limitations of PPSV23:

• Produces T-cell independent responses that do not generate lasting immunologic memory 4
• Does not lead to booster responses on revaccination 4
• Prior PPSV23 administration can blunt subsequent immune responses to PCV13 for all serotypes 6

Clinical Implications for Sequential Vaccination

Optimal Vaccination Sequence:

• Administering PCV13 before PPSV23 (PCV13/PPSV23 sequence) augments the immune response to subsequent PPSV23 for many shared serotypes 6, 7
• In adults 60-64 years, PCV13 followed by PPSV23 one year later produced significantly higher OPA titers for 11 of 12 common serotypes compared to the reverse sequence 6
• The PCV13-priming strategy yields significantly better fold increases in antibody levels, seroconversion rates, and seroprotection rates 7

Problematic Reverse Sequence:

• PPSV23 followed by PCV13 (PPSV23/PCV13) results in diminished responses to subsequent PCV13 for all serotypes 6
• This phenomenon, known as hyporesponsiveness, represents a critical pitfall when sequencing is not optimized 6

Current Guideline Recommendations

For vaccine-naive adults ≥50 years:

• CDC/ACIP now recommends a single dose of PCV20, PCV21, or the PCV15/PPSV23 series as preferred options 8, 9
• PCV13 alone is no longer the primary recommendation due to availability of broader coverage vaccines 10

For adults who previously received only PCV13:

• Complete the series with PCV20, PCV21, or PPSV23 administered ≥1 year after PCV13 for standard risk adults 10
• Immunocompromised adults can receive PPSV23 as early as ≥8 weeks after PCV13 10, 1

Critical timing considerations:

• PCV13 and PPSV23 should never be coadministered on the same day 8
• For immunocompetent adults, maintain ≥1 year interval between vaccines 10
• For immunocompromised patients (HIV, chronic renal failure, malignancy, transplant), the minimum interval is reduced to ≥8 weeks 10, 1

Safety and Tolerability

Both vaccines demonstrate acceptable safety profiles with predominantly mild-to-moderate local reactions 3, 5:

• Common local reactions include injection site pain, redness, and swelling 3
• Systemic reactions include fatigue, headache, decreased appetite, and irritability 3
• Fever occurs in approximately 5-6% of recipients 3
• Safety profiles are comparable between PCV13 and PPSV23 5, 11

Duration of Protection

PCV13:

• Antibody titers decline from 1 month to 1 year post-vaccination but remain above baseline levels 2, 5
• Maintains immunologic memory allowing for potential booster responses 4

PPSV23:

• Provides broader serotype coverage but without sustained immunologic memory 1, 4
• Revaccination does not produce enhanced booster responses due to T-cell independent mechanism 4